Ciprofloxacin for the treatment of uncomplicated gonorrhea infection in adolescents: Does the benefit outweigh the risk?

Clinical Infectious Diseases

Volumn 35, Issue , 2002, Pages S191-S199

  Burstein, Gale R ^a   Berman, Stuart M ^a   Blumer, Jeffery L ^b   Moran, John S ^a  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^b CASE WESTERN RESERVE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZITHROMYCIN; CEFIXIME; CEFTRIAXONE; CIPROFLOXACIN; OFLOXACIN; PENICILLIN DERIVATIVE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TETRACYCLINE;

ADOLESCENT; ANAPHYLAXIS; ANTIBIOTIC RESISTANCE; ARTHRALGIA; ARTICLE; ARTICULAR CARTILAGE; ATAXIA; CARDIOVASCULAR DISEASE; CHILD; CHONDROPATHY; CONTROLLED STUDY; DELIRIUM; DIARRHEA; GASTROINTESTINAL SYMPTOM; GONORRHEA; HAIR LOSS; HALLUCINATION; HUMAN; MAJOR CLINICAL STUDY; NEUTROPENIA; PHOTOSENSITIVITY DISORDER; PRIORITY JOURNAL; RASH; RESPIRATORY TRACT DISEASE; RISK BENEFIT ANALYSIS; SLEEP DISORDER; URTICARIA; VOMITING;

ADOLESCENT; ANTI-INFECTIVE AGENTS; CIPROFLOXACIN; GONORRHEA; HUMANS; RISK ASSESSMENT;

EID: 0037108533     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/342107     Document Type: Article

References (57)

1. Division of STD Prevention. Sexually transmitted disease surveillance, 1999. Atlanta: Centers for Disease Control and Prevention, 2000.
2. Cohen D, Spear S, Scribner R, Kissinger P, Mason K, Wildgen J. "Broken windows" and the risk of gonorrhea. Am J Public Health 2000; 90:181-3.
3. Institute of Medicine. Factors that contribute to the hidden epidemic. In: Eng TR, Butler WT, eds. The hidden epidemic. Washington, DC: National Academy Press, 1997:69-117.
4. Centers for Disease Control. Antibiotic-resistant strains of Neisseria gonorrhoeae. MMWR Morb Mortal Wkly Rep 1987; 36(Suppl 5):1S-18S.
5. McGregor J, Stamm C. Diagnosing and treating STDs in young women. Contemp Pediatr 2001; 18 (2):53-67.
6. Centers for Disease Control and Prevention. Guidelines for treatment of sexually 1998 transmitted diseases. MMWR Morb Mortal Wkly Rep 1998; 47:59-70.
7. Steingrimsson O, Olafsson JH, Thorarinsson H, Ryan RW, Johnson RB, Tilton RC. Azithromycin in the treatment of sexually transmitted diseases. J Antimicrob Chemother 1990; 25(Suppl A):109-14.
8. Waugh M. Open study of the safety and efficacy of a single oral dose of azithromycin for the treatment of uncomplicated gonorrhoea in men and women. J J Antimicrob Chemother 1993; 31 (Suppl E):193-8.
9. Handsfield HH, Dalu ZA, Douglas JD, McCarty JM, Schlossberg D. Multicenter trial of single-dose azithromycin vs ceftriaxone in the treatment of uncomplicated gonorrhea. Sex Transm Dis 1994; 21:107-11.
10. CIPRO® (ciprofloxacin hydrochloride) tablets. In: Physicians desk reference. 55th ed. Montvale, NJ: Medical Economics Company Inc., 2000:847-52.
11. American Academy of Pediatrics. Fluoroquinolones. In: Pickering LK, ed. 2000 red book: report of the Committee on Infectious Diseases. 25th ed. Elk Grove Village, IL: American Academy of Pediatrics, 2000: 645.
12. Schaad UB, Salam MA, Aujard Y, et al. Use of fluoroquinolones in pediatrics: consensus report of an International Society of Chemotherapy commission. Pediatr Infect Dis J 1995; 14:1-9.
13. Burkhardt JE, Walterspiel JN, Schaad UB. Quinolone arthropathy in animals versus children. Clin Infect Dis 1997; 25:1196-204.
14. Echols RM. Introduction: historical perspective - use of ciprofloxacin in children. Pediatr Infect Dis J 1997; 16:89-90.
15. Warren RW. Rhematologic aspects of pediatric cystic fibrosis patients treated with fluoroquinolones. Pediatr Infect Dis J 1997; 16:118-22.
16. Burkhardt JE. Review of quinolone arthropathy in the dog. Chemotherapie J 1996; 5(Suppl 13):14-8.
17. Christ W, Lehnert T, Ulbrich B. Specific toxicologic aspects of the quinolones. Rev Infect Dis 1988; 10(Suppl):S141-6.
18. Schluter G. Toxicology of ciprofloxacin [abstract xx]. In: Proceedings from the 1st International Ciprofloxacin Workshop (Leverkusen, Germany). Amsterdam: Excerpto Medica, 1986;61-7.
19. Stahlmann R, Forster C, Van Sickle D. Quinolones in children. Are concerns over arthropathy justified? Drug Saf 1993; 9:397-403.
20. HHS SSC medical supply catalog 2000. Perry Point, MD: US Department of Health and Human Services Supply Service Center, 2000.
21. Henry Schein medical catalogue. The source 2000 update. Melville, NY: Henry Schein, Inc. 2000.
22. Rubio TT. Ciprofloxacin in the treatment of Pseudomonas infection in children with cystic fibrosis. Diagn Microbiol Infect Dis 1990; 13:153-5.
23. Jawad ASM. Cystic fibrosis and drug-induced arthropathy [letter]. Brit J Rheumatol 1989; 28:179-80.
24. Alfaham M, Holt ME, Goodchild MC. Arthropathy in a patient with cystic fibrosis taking ciprofloxacin [letter]. Br Med J 1987; 295:699.
25. Redmond A, Sweeney L, MacFarland M, Mitchell M, Daggett S, Kubin R. Oral ciprofloxacin in the treatment of Pseudomonas exacerbations of paediatric cystic fibrosis: clinical efficacy and safety evaluation using magnetic resonance image scanning. J Int Med Res 1998; 26:304-12.
26. Pradham KM, Arora NK, Susheela AK, Bhan MK. Safety of ciprofloxacin therapy in children: magnetic resonance images, body fluid levels of fluoride and linear growth. Acta Paediatr 1995; 84:555-60.
27. Richard DA, Nousia-Arvanitakis S, Sollich V, Hampel BJ, Sommerauer B, Schaad UB. Oral ciprofloxacin vs. intravenous cetazidime plus tobramycin in pediatric cystic fibrosis patients: comparison of antiseudomonas efficacy and assessment of safety with ultrasonography and magnetic resonance imaging. Pediatr Infect Dis J 1997; 16:572-8.
28. Singh UK, Sinha RK, Prasad B, Chakrabarti B, Sharma SK. Ciprofloxacin in children: is arthropathy a limitation? Indian J Pediatr 2000; 67:386-7.
29. Schaad UB, Stoupis C, Wedgwood J, Tschaeppeler H, Vock P. Clinical, radiologic and magnetic resonance monitoring for skeletal toxicity in pediatric patients with cystic fibrosis receiving a three-month course of ciprofloxacin. Pediatr Infect Dis J 1991; 10:723-9.
30. Danisovicova A, Brezina M, Belan S, et al. Magnetic resonance imaging in children receiving quinolones: no evidence of quinolone-indced arthropathy. Chemotherapy 1994; 40:209-14.
31. Schaad UB, Sander E, Wedgwood J, Schaffner T. Morphologic studies for skeletal toxicity after prolonged ciprofloxacin therapy in two juvenile cystic fibrosis patients. Pediatr Infect Dis J 1992; 11:1047-49.
32. Phillips BM, David TJ, et al. Pathogenesis and management of arthropathy in cystic fibrosis. J R Soc Med 1986; 79(Suppl 12):44-50.
33. Dixey J, Redington AN, Butler RC, et al. The arthropathy of cystic fibrosis. Ann Rheum Dis 1988; 47:218-33.
34. Church DA, Kanga JF, Kuhn RJ, et al. Sequential ciprofloxacin therapy in pediatric cystic fibrosis: comparative study vs. ceftazidime/tobramycin in the treatment of acute pulmonary exacerbations. Pediatr Infect Dis J 1997; 16:97-105.
35. Rubio TT, Miles MV, Lettieri JT, Kuhn RJ, Echols RM, Church DA. Pharmacokinetic disposition of sequential intravenous/oral ciprofloxacin in pediatric cystic fibrosis patients with acute pulmonary exacerbation. Pediatr Infect Dis J 1997; 16:112-7.
36. Schaad UB, Wedgwood J, Ruedeberg A, Kraemer R, Hampel B. Ciprofloxacin as antipseudomonal treatment in patients with cystic fibrosis. Pediatr Infect Dis J 1997; 16:106-11.
37. Sen S, Goyal Rs, Dev R. Ciprofloxacin in the management of multiple drug resistant typhoid fever. Indian Pediatr 1991; 28:417-9.
38. Salam MA, Dhar U, Khan WA, Bennish ML. Randomised comparison of ciprofloxacin suspension and pivmecillinam for childhood shigellosis. Lancet 1998; 352:522-7.
39. Naccari F, Salpietro DC, De Sarro A, Masaracchio A, Barberi I. Tolerance and pharmacokinetics of ciprofloxacin in the chick. Preliminary experience in subjects of pediatric age with urinary tract infections. Res Commun Molec Pathol Pharmacol 1998; 99:187-92.
40. Lang R, Goshen S, Raas-Rothschild A, et al. Oral ciprofloxacin in the management of chronic suppurative otitis media without cholesteatoma in children: preliminary experience in 21 children. Pediatr Infect Dis J 1992; 11:925-9.
41. Vinh H, Wain J, Hanh VTN, et al. Two or three days of ofloxacin treatment for uncomplicated multidrug-resistant typhoid fever in children. Antimicrob Agents Chemother 1996; 40:958-61.
42. Black A, Redmond AOB, Steen HJ, Oborska IT. Tolerance and safety of ciprofloxacin in paediatric patients. J Antimicrob Chemother 1990; 26(Suppl F):25-9.
43. Jick S. Ciprofloxacin safety in a pediatric population. Pediatr Infect Dis J 1997; 16:130-4.
44. Hampel B, Hullmann R, Schmidt H. Ciprofloxacin in pediatrics: worldwide clinical experience based on compassionate use - safety report. Pediatr Infect Dis J 1997; 16:127-9.
45. Chysky V, Kapila K, Hullmann R, Arcieri G, Schacht P, Echols R. Safety of ciprofloxacin in children: worldwide clinical experience based on compassionate use. Empahsis on joint evaluation. Infection 1991; 19:289-96.
46. Thomsen LL, Paerregaard A. Treatment with ciprofloxacin in children with typhoid fever. Scand J Infect Dis 1998; 30:355-7.
47. Pertuiset E, Lenoir G, Jehanne M, Douchain F, Guillot M, Menkes CJ. Joint tolerance of pefloxacin and ofloxacin in children and adolescents with cystic fibrosis [in French]. Rev Rhumatol 1989; 56:735-40.
48. El-Sherbini A. An outbreak of typhoid fever resistant to chloramphenicol and other drugs in Gharbeya Governorate in Egypt. J Trop Pediatr 1991; 38:331-4.
49. Arico M, Bossi G, Casselli D, et al. Long term magnetic resonance survey of cartilage damage in leukemic children treated with fuoroquinolones [letter]. Pediatr Infect Dis J 1995; 14:713-4.
50. Miller MS, Gaido F, Rourk MH Jr, Spock A. Anaphylactoid reactions to ciprofloxacin in cystic fibrosis patients [letter]. Pediatr Infect Dis J 1991; 10:164-5.
51. Singh J, Agarwa AK, Sudrania SP. Extrapyramidal syndrome following ciprofloxacin treatment [letter]. Indian Pediatr 1994; 31:608-9.
52. Upton C. Sleep disturbances in children treated with ofloxacin [letter]. Br Med J 1994; 309:1411.
53. Rabatoli PV, D’Souza RSD, Chume VG. An unusual hallucination with norfloxacin [letter]. J Assoc Phys India 1996; 44:504.
54. Winrow AP, Supramaniam G. Benign intracranial hypertension after ciprofloxacin administration Arch Dis Child 1990; 65:1165-6.
55. NegGram® (naldixic acid). In: Physicians desk reference. 55th ed. Montvale, NJ: Medical Economics Company Inc., 2000:2857-8.
56. American Academy of Pediatrics. Gonococcal infections. In: Pickering LK, ed. 2000 red book: report of the Committee on Infectious Diseases. 25th ed. Elk Grove Village, IL: American Academy of Pediatrics, 2000:254-60.
57. Moran JS, Levine WC. Drugs of choice for the treatment of uncomplicated gonococcal infections. Clin Infect Dis 1995; 20(Suppl 1): S47-65.